Fitch says US tariffs alone won't trigger EU rating downgrades
One of Fitch's top sovereign analysts, Ed Parker, said the U.S.'s baseline tariff of 15% on imports from the EU was in line with assumptions the rating agency has had since March and therefore did not "materially shift" its economic forecasts.
Nevertheless, the 15% rate is a huge increase relative to the 1.2% rate of last year, he said.
"We don't expect the increase in the tariff rate to directly drive EU rating changes on its own, but it could compound existing credit pressures," Parker told Reuters.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
27 minutes ago
- Reuters
Lilly set for strong quarter after Novo profit warning
July 29 (Reuters) - Investors and analysts say they expect Eli Lilly (LLY.N), opens new tab to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk ( opens new tab did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health. Lilly's weight-loss drug Zepbound leads the U.S. market and has faced less competition from cheaper copies made by compounding pharmacies, giving it an edge, they said, after investors wiped $70 billion from Novo's market value. Novo, which sells the obesity drug Wegovy and related diabetes medicine Ozempic, on Tuesday issued a profit warning, opens new tab, citing lower U.S. growth expectations and competition including from compounded versions. "I think that this is a pretty positive report for Lilly just because it shows the competitive note it has against their largest competitor," said Dave Wagner, portfolio manager at Aptus Capital Advisors. Analysts expect Lilly to post second-quarter earnings of $5.57 per share on revenue of $14.71 billion, according to LSEG data. They are also looking for a full-year profit of $21.83 per share. Lilly has forecast adjusted earnings of $20.78 to $22.28 per share for 2025. Still, Lilly's shares fell nearly 5% on Tuesday, reflecting concern that the company could be vulnerable if Novo cuts prices aggressively or if its growth in the obesity market also slows more than expected, analysts and investors said. Zepbound holds just under 60% of the obesity market, while Lilly's diabetes drug Mounjaro - containing the same active ingredient - accounts for over half of its segment against Ozempic, according to IQVIA data shared with Reuters by an analyst. IQVIA did not immediately respond to a request for confirmation. UBS analyst Trung Huynh said data also showed Lilly was getting around two-thirds of new patients onto Zepbound. The company in December posted results from a large head-to-head trial showing patients on Zepbound lost an average of 20.2% of their weight after 72 weeks compared to 13.7% for the group treated with Wegovy. Lilly is also expected to be first to the market with the next generation of oral obesity drugs. Lilly has said it intends to seek approval for its experimental drug orforglipron by the end of the year. Lilly has felt less heat from compounded versions of its medicines than Novo Nordisk, Huynh said, largely because Wegovy and Ozempic both hit the market before Lilly's drugs and built up patient recognition sooner. Compounding pharmacies earlier this year were restricted under U.S. law from making drugs that were essentially copies of Wegovy and Zepbound, but can still make personalized doses for patients who need them, or formulations not offered by FDA-approved medicines. Investors earlier this year were rattled by CVS Health's (CVS.N), opens new tab decision to drop Zepbound from some lists of medicines it covers for reimbursement starting on July 1, triggering a 10% share price plunge. But Lilly's stock has declined marginally so far this year, compared to a more than 40% fall in Novo Nordisk's shares, including Tuesday's moves. Barclays analyst Emily Field said Lilly could calm investors next week by reaffirming or boosting revenue and profit outlooks, or simply by delivering strong financial results. Brian Mulberry at Zacks Investment Management said signs of softness in the obesity or diabetes drug market, especially from a peer like Novo, typically trigger broad-based selling, which might account for Lilly's share drop on Tuesday.
Reuters
27 minutes ago
- Reuters
Oil prices rally on US pressure on Russia, trade deal optimism
NEW YORK, July 29 (Reuters) - Oil prices gained more than 3% on Tuesday as President Donald Trump ramped up pressure on Russia over its war in Ukraine and on optimism that a trade war between the U.S. and its major trading partners was abating. Brent crude futures settled $2.47, or 3.53%, higher at $72.51 a barrel while U.S. West Texas Intermediate crude gained $2.50, or 3.75%, to settle at $69.21. Both contracts settled at their highest since June 20. On Tuesday, Trump said he would start imposing tariffs and other measures on Russia "10 days from today" if Moscow did not make progress toward ending the war in Ukraine. "We've amped it up. We have a hard deadline of 10 days," said Phil Flynn, senior analyst with Price Futures Group. "And there's a suggestion that other countries are going to join us." Also on Tuesday, U.S. Treasury Secretary Scott Bessent said he had told Chinese officials that, given U.S. secondary tariff legislation on sanctioned Russian oil, China could face high tariffs if Beijing continued its Russian oil purchases. Bessent was speaking after two days of bilateral talks aimed at resolving longstanding economic disputes and stepping back from an escalating trade war between the world's two biggest economies. Also supporting oil prices, the trade agreement between the U.S. and the European Union, while imposing a 15% import tariff on most EU goods, sidestepped a full-blown trade war between the two major allies that would have rippled across nearly a third of global trade and dimmed the outlook for fuel demand. "There is definitely some optimism around the trade deals," said Bob Yawger, director of energy futures at Mizuho. "It's not perfect, especially for the Europeans, but it is better than it could have been by a long shot." The agreement also calls for $750 billion of EU purchases of U.S. energy over the next three years, which analysts say the bloc has virtually no chance of meeting, while European companies are to invest $600 billion in the U.S. over Trump's term. Market participants also await the outcome of the U.S. Federal Reserve policy meeting on Tuesday and Wednesday. The Fed is widely expected to hold rates steady but could signal a dovish tilt due to signs of cooling inflation, said Priyanka Sachdeva, senior market analyst at brokerage Phillip Nova.
Reuters
an hour ago
- Reuters
Brazil is planning relief measures for firms hit by US tariffs, says minister
BRASILIA, July 29 (Reuters) - Brazil is planning relief measures for companies impacted heavily by steeper U.S. tariffs set to take effect in August, Finance Minister Fernando Haddad said on Tuesday. Speaking to CNN Brasil, Haddad said the plan, which will be reviewed by President Luiz Inacio Lula da Silva, includes steps to ensure companies have the confidence to maintain their investments. He denied, however, that the plan includes tax exemptions for the affected companies. Earlier on Tuesday, Ports and Airports Minister Silvio Costa Filho said the government would support planemaker Embraer ( opens new tab, citing a potential additional credit line for the company. Crude oil, coffee, orange juice, beef, and aircraft - mainly from Embraer - are among Brazil's top exports to the United States. Haddad said the government still lacks clarity on what exactly will come from the U.S. starting on August 1, the date U.S. President Donald Trump has set to hike tariffs on Brazilian imports to the U.S. to 50% from the current 10%. The minister said Brazil could see a positive surprise in food inflation due to the tariffs' impact on sectors such as beef and fruit, noting that domestic prices appear to be falling as a result of increased supply in the local market. Haddad also said Latin America's largest economy cannot make the "symmetrical mistake" of retaliating in the same areas targeted by the U.S. tariffs, which he said would amount to responding in kind and ultimately punishing Brazilian consumers. "I cannot anticipate decisions that have not been made," he said, when asked whether taxing big tech companies was among the retaliation measures under consideration.
